CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Nabriva Therapeutics PLC - ADR is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Nabriva Therapeutics PLC - ADR
Alexandra House Office 225/227
, The Sweepstakes,, Ballsbridge
Phone: +353 6108166640p:+353 6108166640 DUBLIN, D01 H104  Ireland Ticker: NBRVFNBRVF
This company ceased filing statements with the SEC on 10/25/2023.
Business Summary
Nabriva Therapeutics PLC is a biopharmaceutical company. The Company is engaged in the commercialization and development of anti-infective agents to treat serious infections. The Company's product is XENLETA (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). XENLETA is designed to inhibit the synthesis of a specific protein on the bacterial ribosome, which is required for bacteria to grow, by binding with high affinity and specificity at molecular targets that are different than other available antibiotic classes causing cell death.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
8732 Commercial economic, sociological, and educational research
2834 Pharmaceutical preparations
8699 Membership organizations, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Daniel D.Burgess 62 6/23/2017 6/23/2017
Chief Executive Officer H. MichaelHogan 60 7/6/2023 7/6/2023
Chief Financial Officer DaveMaggio 64 6/30/2023 6/30/2023
5 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
NABRIVA THERAPEUTICS IRELAND DESIGNATED ACTIVITY COMPANY ALEXANDRA HOUSE OFFICE 225/227 THE SWEEPSTAKES IE
Zavante Therapeutics, Inc. 11750 Sorrento Valley Road San Diego CA United States
Nabriva Therapeutics US, Inc. 414 COMMERCE DR STE 120 FORT WASHINGTON PA US

Business Names
Business Name
Nabriva Therapeutics Ireland Designated Activity Company
Nabriva Therapeutics US, Inc.
Nabriva Theraupeutics GmbH
7 additional Business Names available in full report.

General Information
Number of Employees: 39 (As of 1/31/2023)
Outstanding Shares: 3,230,837 (As of 8/11/2023)
Shareholders: 24
Stock Exchange: OTC


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024